

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated March 8, 2022.

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on March 8, 2022 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk’s MindBio Therapeutics announces platinum sponsorship of Plant Medicine Week in Malta.

Item 5. Full Description of Material Change

Vancouver, British Columbia – March 8, 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “**Corporation**” or “**Blackhawk**”) is pleased to report that MindBio Therapeutics (“MindBio”) is a key note presenter and major supporter of Plant Medicine Week in Malta.

Plant Medicine Week (plantmedicineweek.com) is being held in Valletta, Malta in April (5th – 8th) to share diverse and inspiring perspectives of the latest advances from the medical cannabis and psychedelics industries through case studies, presentations, Q&A and exhibition.

Co-founder of MindBio Therapeutics, Justin Hanka, will be sharing his perspectives on clinical trials, drug development and his views on the responsibility to change the course of mental health and the importance of investment in the sector. Recently Mr Hanka participated in Microdose Psychedelic Insights molecular masterclass on LSD (lysergic acid diethylamide) which can be viewed on Youtube [here](#).

MindBio Therapeutics is in the completion stages of a world first clinical trial in 80 patients who are microdosing LSD at home. The Clinical Trial’s Independent Review Board and Safety Monitoring Committee recently found no adverse events in the Phase 1 clinical trial and approved it’s continuation, with almost 12 months of testing now complete. MindBio is now preparing for its continuation study, a Phase 2 clinical trial microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial

microdosing LSD in late stage cancer patients experiencing existential distress, depression and anxiety.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system with the aim of changing the course of mental health.

“We are excited to support Plant Medicine Week in Malta and showcase our clinical trials microdosing psychedelic medicines as MindBio prepares for its upcoming spin-out listing on the Canadian Securities Exchange” said Frederick Pels, CEO of Blackhawk.

Plant Medicine Week. More information and tickets available [here](#).

Microdose Molecular Masterclass video by MindBio Co-Founder Justin Hanka can be viewed on Youtube [here](#).

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods Co., MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel <https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A>

Please join the conversation on our Blackhawk group supporter’s telegram group at <https://t.me/Blackhawkgrowthcorp> and visit us online at <https://www.blackhawkgrowth.com>.

For further information please contact:

Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com

.Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable

Item 7. Omitted Information
Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

March 8, 2022